# EDGAR Filing Document

**Accession Number:** 0001840748
**File Stem:** 0001104659-25-121581
**Filing Date:** 2025-12
**Character Count:** 2874
**Document Hash:** 1d2a04f033c99028b432237d6e6aa7a5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-121581.hdr.sgml**: 20251216

**ACCESSION NUMBER**: 0001104659-25-121581

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251216

**DATE AS OF CHANGE**: 20251216

**EFFECTIVENESS DATE**: 20251216

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LAVA Therapeutics NV
- **CENTRAL INDEX KEY:** 0001840748
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40241
- **FILM NUMBER:** 251575331

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** YALELAAN 62
- **CITY:** UTRECHT
- **PROVINCE COUNTRY:** P7
- **BUSINESS PHONE:** 31 6 3000 3035

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** YALELAAN 62
- **CITY:** UTRECHT
- **PROVINCE COUNTRY:** P7

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LAVA Therapeutics BV
- **DATE OF NAME CHANGE:** 20210115

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 15**

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION**

**UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934**

**OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934.**

**001-40241**

**Commission File Number**

**LAVA THERAPEUTICS N.V.**

**(Exact name of registrant as specified in its charter)**

**2200 Powell Street, Suite 310**

**Emeryville, California 94608**

**(510) 204-7200**

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)**

**Common Shares, €0.12 nominal value**

**(Title of each class of securities covered by this Form)**

**None**

**(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)**

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
| Rule 12g-4(a)(1) | ⌧ |
| Rule 12g-4(a)(2) | ◻ |
| Rule 12h-3(b)(1)(i) | ⌧ |
| Rule 12h-3(b)(1)(ii) | ◻ |
| Rule 15d-6 | ◻ |
| Rule 15d-22(b) | ◻ |

---

Approximate number of holders of record as of the certification or notice date: One

Pursuant to the requirements of the Securities Exchange Act of 1934, Lava Therapeutics N.V. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | |
|:---|:---|:---|
| Date: December 16, 2025 | **LAVA THERAPEUTICS N.V.** | **LAVA THERAPEUTICS N.V.** |
|  | By: | /s/ Owen Hughes |
|  |  | Name: Owen Hughes |
|  |  | Title: *Director* |

---